Capital hasn’t disappeared—it’s just gotten more selective. In 2025, digital health investors aren’t just backing storylines. They’re backing systems and teams that can navigate procurement, prove buyer urgency, and implement without chaos.
U.S. digital health funding edged up to $17.2 billion in 2024, a 4% year-over-year increase—breaking a two-year decline, according to Galen Growth. Capital is still flowing, but into tighter lanes.
Below are 17 digital health investors worth knowing — including the most active investors in U.S. digital health ventures last year.
Are you an investor not listed here with an interest in being added? Please get in touch.
1. Oak HC/FT
Website: oakhcft.com
Focus: Healthcare and fintech, with deep investments in care delivery, payer platforms, and revenue cycle transformation
Notable investments: Athenahealth, Benefitfocus, Castlight Health, PharMEDium, and others
Fund size: Closed Fund V at $1.94B (2023); $5.3B+ AUM
Why it matters: Oak backs the plumbing. They’re backing the infrastructure that makes care more navigable — payment rails, benefits layers, clinical logistics. If you’re working on cost-of-care, complex populations, or cross-system coordination, this is a fund that evaluates for durability and operational fit.
2. Bessemer Venture Partners
Website: bvp.com
Focus: Enterprise health tech, virtual care, and AI-enablement
Notable investments: Hinge Health, Abridge, Bright Health, Qventus, Alcresta Therapeutics, and others
Fund size: $3.85B in latest fund; $20B+ AUM
Why it matters: Bessemer is one of the oldest venture firms (established in 1911), but they’re not stuck in the past. They’ve backed 68 unicorns and 64 IPOs, and they’re still early believers in AI-native healthcare platforms, vertical SaaS, and global marketplaces. Their “anti-portfolio” is a reminder they’ve missed some big ones — but their actual portfolio (which includes LinkedIn and Shopify) is a masterclass in long-term conviction.
3. Flint Capital
Website: flintcap.com
Focus: Early-stage digital health, women’s health, and mental health, with a strong emphasis on supporting immigrant founders from Europe and Israel aiming to enter the U.S. market.
Notable investments: Flo, Sensi.AI, XRHealth, Antidote Health, and others
Fund size: $160M (Fund III, 2023)
Why it matters: Flint Capital may not be the most high-profile firm, but they’ve built a reputation for backing founders who bridge global markets. Their portfolio includes companies like Flo Health and Sensi.AI, reflecting a focus on digital health solutions with international roots. Flint’s strategy of supporting immigrant entrepreneurs and facilitating their expansion into the U.S. market has led to notable successes, including Socure and WalkMe. For founders seeking a partner attuned to cross-border growth and operational support, Flint offers a compelling proposition.
4. SV Health Investors
Website: svhealthinvestors.com
Focus: Early- to growth-stage investments in biotech, medtech, and healthcare services, with a particular emphasis on neurodegenerative diseases and dementia.
Notable investments: Amwell, EyeBio, Insulet, Incyte, Adapt Health, Adimab, Alpheaus Medical, and others
Fund size: ~$2B AUM
Why it matters: SV Health Investors is a specialist healthcare fund manager with a track record of investing in companies addressing significant unmet medical needs. Their recent $250 million fund dedicated to dementia and neurodegenerative diseases underscores their commitment to tackling some of the most challenging areas in healthcare. For founders in the biotech and medtech space, SV Health Investors offers deep industry expertise and a focused investment approach.
5. Health Velocity Capital
Website: healthvelocitycapital.com
Focus: Software and services that improve access, outcomes, and efficiency
Notable investments: ShiftKey, Ginger, Compass Surgical, Hummingbird, and others
Fund size: Not publicly disclosed
Why it matters: Health Velocity Capital helps digital health companies grow by plugging in senior operators, board members, and key hires from within their network. Their partners include executives from organizations that insure 175 million Americans, run more than 700 hospitals, and touch over 75% of the U.S. healthcare market. That gives them a direct line into what payers and providers are actually prioritizing.
For founders building in care delivery, behavioral health, or labor enablement, HVC brings access to how decisions get made across the system.
6. a16z Bio + Health
Website: a16z.com/bio-health
Focus: Where biology, software, and AI meet care
Notable investments: Omada, Freenome, Q Bio, BioAge Labs, and others
Fund size: $3B+ AUM
Why it matters: In 2024, Andreessen Horowitz completed 26 U.S. digital health deals, making it the most active investor in the sector that year. Through a16z Bio + Health, they back teams operating at the intersection of AI, biology, and care delivery — often before it’s obvious how those bets will commercialize. Their investment approach pairs long-horizon science with infrastructure-scale ambition, a theme they explore regularly through conversations on their Raising Health podcast.
Founders tackling both scientific and commercial complexity often find alignment here — and support that reflects real operator experience and a willingness to invest across the arc from seed to scale.
7. General Catalyst (Health Assurance)
Website: generalcatalyst.com/health-assurance
Focus: System-level transformation via payer/provider alignment
Notable investments: Cityblock, Commure, Livongo, Maven Clinic, and others
Fund size: $750M Health Assurance Fund II (2024); closed $8B in new capital as of 2024
Why it matters: General Catalyst is investing to re-architect healthcare—not just fund startups. Through formal partnerships with health systems like HCA and Jefferson Health, they embed companies into clinical workflows and deploy at scale. Their Health Assurance thesis favors companies with system-wide relevance: interoperable infrastructure, clinically embedded AI, and models that align with how care is actually delivered.
General Catalyst completed 25 U.S. digital health deals in 2024, making it the second most active investor in the sector.
8. Define Ventures
Website definevc.com
Focus: Early-stage digital health: consumer platforms, infrastructure, navigation
Notable investments: Hims & Hers, Unite Us, Cohere Health, Folx Health, and others
Fund size: $460M+ across three funds; $800M+ AUM
Why it matters: Define focuses on early-stage digital health companies. The team blends deep healthcare expertise with a track record in tech-enabled services and go-to-market execution. 72% of their portfolio companies sell into leading health systems, and they’ve helped place senior talent or advisors at two-thirds of them.
With $23B in exit value across companies like Livongo and Hims & Hers, Define brings operational clarity on what it actually takes to scale in healthcare.
9. Optum Ventures
Website: optumventures.com
Focus: Data-driven care navigation and platform infrastructure
Notable investments: DispatchHealth, LetsGetChecked, Unite Us, Synapticure and others
Fund size: $2B+ across multiple funds
Why it matters: With more than 70 portfolio companies, Optum Ventures has become a key commercialization partner for digital health startups. Backed by UnitedHealth Group, they offer access to deployment across payers, providers, and employers.
For companies building infrastructure that needs to plug into existing clinical or administrative systems, OV brings tested channels and operational context.
10. Transformation Capital
Website: transformcap.com
Focus: Commercial-stage companies with real-world traction
Notable investments: Sword Health, Capital Rx, Groups Recover Together, and others
Fund size: $800M+ AUM
Why it matters: Transformation Capital brings deep healthcare expertise and a focus on companies ready to scale. They invest in post-pilot businesses with real traction — like DexCare’s $50 million Series B — and work closely with teams to navigate growth in complex healthcare markets.
With leadership that includes former Sequoia investor Mike Dixon, they offer operational insight, strategic guidance, and long-term partnership grounded in sector depth.
11. Flare Capital Partners
Website: flarecapital.com
Focus: Early-stage healthcare technology, with emphasis on reducing clinical and administrative costs, improving outcomes, and supporting scalable platforms across the care continuum.
Notable investments: HealthifyMe, Aetion, Bright Health, HealthVerity, Somatus, Tausight, VisitPay and more
Fund size: $350 million (Flare Capital Partners III, closed in 2022)
Why it matters: Flare Capital was also one of the most active U.S. digital health investors in 2024, with 16 deals including a $20 million investment in HealthifyMe. The firm partners with founders across all stages—early to exit—and prioritizes companies that address major market opportunities and systemic inefficiencies in healthcare. With a strong network of payers, providers, and operators, Flare supports startups focused on measurable improvements in access, quality, and cost.
12. Alumni Ventures
Website: av.vc
Focus: Broad healthcare and tech investing across stages, with co-investments alongside established lead investors and a disciplined, diversified approach
Notable investments: Oshi Health, Centaur Labs, Legion Health and more
Fund size: $1.3 billion+ raised since 2014
Why it matters: Alumni Ventures operates a network-powered model, with over 1,400 portfolio companies and around ~40 full-time investors. This structure is built for broad deal access, syndication, and co-investment with leading firms—making them one of the most plugged-in venture platforms in the market. The firm has been ranked a top 3 most active U.S. VC by PitchBook (2018–2024) and was named a top 20 VC by CB Insights in 2024. It was also one of the top five most active U.S. digital health investors in 2024, completing 14 deals, including Oshi Health and Centaur Labs.
13. Khosla Ventures
Website: khoslaventures.com
Focus: AI-powered healthcare, digital health, medtech, and diagnostics — with a strong emphasis on bold, early bets and technology-led disruption across large markets.
Notable investments: Sword Health, Hello Heart, AliveCor, C the Signs, Limbic and more
Fund size: Seeking $3.5 billion across funds (2025)
Why it matters: Khosla backs AI-first healthcare startups with strong technical depth and clear clinical use. In 2024, it led Rad AI’s $50 million Series B—now used by over a third of U.S. health systems—and backed C the Signs, which helps clinicians detect cancer earlier through EHR-based AI. The firm was one of the five most active digital health investors last year, with 11 deals. For founders building transformative tech with clinical traction, Khosla brings early conviction and sharp technical judgment.
14. Scrub Capital
Website: scrubcapital.com
Focus: Early-stage healthcare startups, especially in digital health, health IT, tech-enabled services, and class I/II medical devices
Notable investments: Posterity Health, Conceivable Life Sciences
Fund size: $100K–$300K in pre-seed, seed, and some Series A
Why it matters: Scrub Capital brings frontline clinical insight to venture. With a 650-member network of practicing healthcare professionals and a team that includes clinicians, operators, and health tech storytellers like Christina Farr, the firm is built to spot care delivery pain points early. Scrub embeds clinicians in sourcing, diligence, and portfolio support—offering founders real-world context and access to healthcare’s decision-makers.
15. HealthX Ventures
Website: healthxventures.com
Focus: Digital health solutions that make healthcare safer, more efficient, and more affordable.
Notable investments: Dyania Health, Cardamom Health, Medsense Health and more
Fund size: Over $20 million (initial fund), with an additional $15 million committed in 2024 by the Wisconsin Investment Fund
Why it matters: Based in Madison, Wisconsin, HealthX Ventures specializes in early-stage investments in digital healthcare. The firm supports startups that deliver easy-to-use, cost-effective, and scalable solutions aimed at improving healthcare delivery and outcomes. Led by managing partner Mark Bakken and partner Kristi Ebong, the team brings deep industry expertise and strong operational support.
16. Redesign Health
Website: redesignhealth.com
Focus: Building and launching healthcare startups, particularly those leveraging AI and digital solutions
Notable investments: Stitch PEO, Harmonic Health, Vitalic Health, Jabra Enhance, and more
Fund size: $175 million (latest fund)
Why it matters: Since its launch in 2018, Redesign Health has helped build over 60 companies that have impacted more than 15 million lives. With a focus on addressing core system challenges—like labor shortages, interoperability, and equitable access—they provide the capital, infrastructure, and network needed to go from concept to scale. For founders navigating opaque value chains and complex commercialization paths, Redesign offers hands-on support across ideation, validation, and execution.
17. Summit Impact Partners
Website: summitimpact.partners
Focus: Early-stage investments in biotech and healthcare companies leveraging artificial intelligence and machine learning
Notable investments: Caravan Biologix, Chimeron Bio, Project Oraxis, Kermode Biotechnologies and more
Fund size: Not publicly disclosed
Why it matters: Summit Impact Partners is a venture studio and investment firm building and scaling AI-enabled biotech startups. Based in Colorado, they support companies across cardiometabolic disease, oncology, rare disorders, and more—combining early-stage capital with incubator resources and deep domain expertise. The team is led by Afshin Safavi (CEO), Thomas Malcolm, PhD, and Mahmoud Mahmoudian, PhD—veterans in venture capital and biotech who bring decades of experience, over $6 billion in investor returns, and 25 FDA-approved drugs between them. If you’re working on science that needs to scale—across wet lab, clinic, and market—Summit offers the technical depth and operating experience to help you get there.
What’s Moving Capital in 2025
The market hasn’t gone cold—it’s just more focused. If you’re raising in 2025, it helps to understand the themes that are still generating real movement.
| Theme | Why it matters |
| AI with real impact in care | AI captured 58% of U.S. digital health funding in 2024. Investors are backing AI tools with proven clinical or operational value. That includes documentation platforms, diagnostic engines, and tools that actually reduce provider workload. |
| TechBio and clinical acceleration | Platforms that speed up drug discovery or reduce trial costs (like Formation Bio and Mirador Therapeutics) are attracting mega-deals. Investors want better science, faster. |
| Operational tools that reduce waste | Tools like Abridge, which cut clinical overhead or streamline documentation through generative AI, are a priority for overburdened systems. Investors are favoring back-end solutions that make workflows less chaotic. |
| Obesity care platforms | GLP-1 medications are reshaping how obesity is treated. Digital platforms supporting treatment plans, monitoring, and patient engagement like Noom are seeing strong growth. |
| Mental health and oncology | These are still top therapeutic bets. In 2024, oncology led all categories in U.S. healthtech funding with $2.44B, and mental health followed with $1.94B. Investors are backing precision-driven, scalable approaches. |
| Consolidation and ecosystem plays | 70% of global M&A in 2024 was venture-to-venture. Investors are favoring platforms that can expand via partnerships or acquisition—not just build another point solution. |
| Policy watch and timing | Funding slowed in Q4 2024 as the market awaited signals from the incoming administration. Investors are closely watching how the administration addresses AI regulation, reimbursement, and interoperability, with expectations of capital reacceleration in mid-2025. |
These trends reinforce what we’re seeing on the ground: buyers are saying yes to solutions that save time, cut costs, or speed up development. If you’re not connecting your traction to these priorities, it’s going to be a tough raise.
Getting Investor-Ready Now
More than ever, investor readiness mirrors commercial readiness. If you can’t sell it, you probably can’t raise on it. Here’s what teams that are still closing look like:
- Start with your buyer: If they don’t control budget—or don’t feel urgency—you’re selling into noise.
- Map traction into system logic: A few pilots don’t make a platform. Show how wins turn into repeatable, scalable motion.
- Test your model at 10x: Can procurement swallow your pricing? Can implementation scale without headcount bloat?
- Position to the investor’s lens: Every fund has a POV. Don’t bend your story—sharpen where it fits their thesis and where it already shows up in your pipeline.
Learn the 5 questions digital health investors are now asking on our blog.
Final Thoughts
You don’t need 50 intros. You just need the right three.
If you’re heading into a raise, rethinking your position, or trying to move from “interesting” to institutionally fundable—we can help.
At Accretive Edge, we help founders pressure-test and refine their investor story so it reflects what buyers will actually fund, adopt, or scale — not just what sounds good in a pitch.
